Charles Schwab Investment Management Inc. Purchases 12,657 Shares of Revvity, Inc. (NYSE:RVTY)

Charles Schwab Investment Management Inc. increased its stake in Revvity, Inc. (NYSE:RVTY - Free Report) by 1.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 843,145 shares of the company's stock after acquiring an additional 12,657 shares during the period. Charles Schwab Investment Management Inc. owned about 0.69% of Revvity worth $94,103,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the stock. JPMorgan Chase & Co. lifted its position in Revvity by 13.7% in the third quarter. JPMorgan Chase & Co. now owns 344,115 shares of the company's stock valued at $43,961,000 after purchasing an additional 41,497 shares during the last quarter. Contravisory Investment Management Inc. boosted its position in Revvity by 1,715.9% during the 4th quarter. Contravisory Investment Management Inc. now owns 69,186 shares of the company's stock valued at $7,722,000 after buying an additional 65,376 shares during the period. Bretton Capital Management LLC bought a new stake in Revvity in the 3rd quarter worth $1,405,000. FMR LLC grew its holdings in Revvity by 40.8% in the 3rd quarter. FMR LLC now owns 155,556 shares of the company's stock worth $19,872,000 after acquiring an additional 45,040 shares during the last quarter. Finally, Janney Montgomery Scott LLC increased its position in shares of Revvity by 87.0% in the fourth quarter. Janney Montgomery Scott LLC now owns 7,891 shares of the company's stock valued at $881,000 after acquiring an additional 3,672 shares during the period. 86.65% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Insider Activity

In related news, insider Tajinder S. Vohra sold 5,492 shares of the firm's stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $116.81, for a total transaction of $641,520.52. Following the completion of the sale, the insider now owns 19,652 shares of the company's stock, valued at $2,295,550.12. This trade represents a 21.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Joel S. Goldberg sold 15,170 shares of the company's stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $126.73, for a total value of $1,922,494.10. Following the completion of the transaction, the insider now directly owns 33,400 shares in the company, valued at $4,232,782. This trade represents a 31.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.60% of the company's stock.

Revvity Stock Down 1.1 %

NYSE RVTY traded down $1.23 during trading hours on Thursday, reaching $110.29. 1,225,030 shares of the company's stock traded hands, compared to its average volume of 955,800. The firm has a market cap of $13.25 billion, a PE ratio of 49.91, a PEG ratio of 3.82 and a beta of 1.06. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.60 and a quick ratio of 3.03. Revvity, Inc. has a 52-week low of $97.32 and a 52-week high of $129.50. The firm has a 50-day simple moving average of $117.08 and a 200 day simple moving average of $118.10.

Revvity (NYSE:RVTY - Get Free Report) last issued its quarterly earnings results on Friday, January 31st. The company reported $1.42 EPS for the quarter, topping analysts' consensus estimates of $1.37 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. During the same period in the previous year, the company posted $1.25 EPS. Sell-side analysts anticipate that Revvity, Inc. will post 4.94 EPS for the current fiscal year.

Revvity Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 9th. Stockholders of record on Friday, April 18th will be paid a $0.07 dividend. The ex-dividend date of this dividend is Thursday, April 17th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.25%. Revvity's dividend payout ratio is currently 12.67%.

Analyst Ratings Changes

Several research firms recently issued reports on RVTY. Raymond James reissued an "outperform" rating and issued a $145.00 target price (up from $140.00) on shares of Revvity in a research note on Monday, February 3rd. KeyCorp lifted their price objective on Revvity from $132.00 to $145.00 and gave the stock an "overweight" rating in a research report on Monday, February 3rd. Sanford C. Bernstein downgraded Revvity from an "outperform" rating to a "market perform" rating and set a $130.00 target price for the company. in a report on Friday, January 10th. Barclays lifted their price target on shares of Revvity from $135.00 to $140.00 and gave the company an "overweight" rating in a report on Monday, February 3rd. Finally, Bank of America upgraded shares of Revvity from a "neutral" rating to a "buy" rating and set a $138.00 price objective for the company in a report on Friday, December 13th. Four equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $136.25.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.